TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06683391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment
Description: The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment
Description: The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment
Description: The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.
Study: NCT05010564

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy
Description: Three dose levels will be evaluated with the opportunity to dose de-escalate (dose level -1) for toxicity.~DL-1: 3x10\^6 cells/m2~DL1: 1×10\^7 cells/m2~DL2: 3×10\^7 cells/m2~DL3: 1×10\^8 cells/m2~Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of fludarabine)must be completed greater than or equal to 48 hours prior to infusion of CAR-T cells.~The protocol will allow for up to three additional infusions of the CAR-T product for subjects who meet criteria for retreatment.
Study: NCT06682429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
Study: NCT06683300

Intervention type: DRUG
Intervention: DAPT for 3 months after vertebral artery stenting
Description: After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.
Study: NCT06685432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: The effect of motivational interviewing techniques was examined in addition to diet treatment. The effect of motivational interviewing techniques on anthropometric measurements before and after the study was evaluated. The participants' indecisiveness was investigated and a self-directed change conversation was presented. Behavior change strategies including determining positive and negative aspects, using importance and confidence scales, and setting the agenda were applied by the researcher.~In the interviews that included motivational interviewing techniques:~1. A participant-centered interview was conducted by collaborating with the participant.~2. The researcher was impartial and did not assume the role of an expert.~3. At the beginning of the interview, an evaluation of what was discussed in the previous week was made.~4. First of all, an attempt was made to determine the agenda according to the topic the participant wanted to discuss.~5. The importance scale was used (1-10).
Study: NCT05664152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1111
Description: BARYCELA inj.
Study: NCT02933554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embospheres Microspheres
Description: Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
Study: NCT06507046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Mechanical or Personalized alignment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Description: Mechanical or Personalized alignment
Study: NCT06415357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Healthy Choices (mHC)
Description: mHC is a four-session computer-delivered intervention based on the Information-Motivation-Behavioral (IMB) model and socioecological model (SEM). Using motivational interviewing, it tailors content to participants' responses. Sessions 1 and 2 focus on HIV self-management and alcohol reduction, gauging importance, confidence, and goals. Strengths, barriers, resources, and strategies are explored. Sessions 3 and 4 review goals, reinforce importance, confidence, and motivation, and strategize behavior maintenance. Over two months, participants engage in goal-oriented sessions, promoting sustained behavior change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Healthy Choices (mHC)
Description: mHC is a four-session computer-delivered intervention based on the Information-Motivation-Behavioral (IMB) model and socioecological model (SEM). Using motivational interviewing, it tailors content to participants' responses. Sessions 1 and 2 focus on HIV self-management and alcohol reduction, gauging importance, confidence, and goals. Strengths, barriers, resources, and strategies are explored. Sessions 3 and 4 review goals, reinforce importance, confidence, and motivation, and strategize behavior maintenance. Over two months, participants engage in goal-oriented sessions, promoting sustained behavior change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Text Messaging (MTM)
Description: Text messages with motivational statements will be sent to participants based on their readiness to change, as assessed during mHC session 1. The statements promoting HIV self-management and alcohol use reduction will be derived from an MTM library written by Zambian young people living with HIV. MTM will be delivered to participants daily for two months and weekly for an additional four months at a time that a participant prefers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Text Messaging (MTM)
Description: Text messages with motivational statements will be sent to participants based on their readiness to change, as assessed during mHC session 1. The statements promoting HIV self-management and alcohol use reduction will be derived from an MTM library written by Zambian young people living with HIV. MTM will be delivered to participants daily for two months and weekly for an additional four months at a time that a participant prefers.
Study: NCT06227975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BMS-986368
Description: Specified dose on specified days
Study: NCT05836350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4.8 g/m^2/day NaPB
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4.8 g/m^2/day placebo
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
Study: NCT06415357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART Counseling
Description: All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard ART Counseling
Description: All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard ART Counseling
Description: All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.
Study: NCT04806984

Intervention type: OTHER
Intervention: Participant outreach
Description: Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.

Intervention type: OTHER
Intervention: Participant outreach
Description: Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.
Study: NCT06415357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard ART Counseling
Description: All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.
Study: NCT06243705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Pet
Description: The robot-pet makes sounds like a real cat and responds to touch and petting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Glasses
Description: VR glasses allow you to see videos and films projected on the screen more realistic. With its filtering feature, it combines two different images in the brain and provides the perception of depth in the image and creates a 3D space environment
Study: NCT05174832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 IV days 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 IV days 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 125 mg/m2 IV days 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m2 IV days 1 and 8 of each 21-day cycle
Study: NCT05838807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Ultrasound
Description: Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound
Description: Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Ultrasound
Description: Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ultrasound
Description: Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
Study: NCT05174832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg IV every 21 days
Study: NCT06525766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05872373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snakebite prevention and first aid
Description: The study will offer a communication strategy to develop an effective narrative by using a mix-media campaign, where IEC materials would be chiefly localized.
Study: NCT05174832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg PO BID
Study: NCT05589870

Intervention type: OTHER
Intervention: Multi-drug analysis of polypharmacy treatment
Description: Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment

Intervention type: OTHER
Intervention: Multi-drug analysis of polypharmacy treatment
Description: Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment
Study: NCT05892315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated subgingival instrumentation
Description: Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supragingival scaling
Description: Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
Study: NCT05651854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama breathing
Description: Bhramari and sheetali pranayama breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama breathing
Description: Bhramari and sheetali pranayama breathing
Study: NCT05794776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BurstDR stimulation
Description: BurstDR spinal cord stimulation
Study: NCT04675450

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBP Softgel Capsules
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
Study: NCT06319417

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HT treatment
Description: Total consumption of 60 mg/day of HT

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Consumption of placebo treatment of 4 caramels/day
Study: NCT05794776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonic stimulation
Description: Tonic spinal cord stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No stimulation
Description: Stimulator is switched off
Study: NCT05979753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS
Description: EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS
Description: EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER
Study: NCT05649111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Difluprednate Eye Drops
Description: post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
Study: NCT05672147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD33 CAR T-cells
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphodepletion Therapy
Description: Undergo lymphodepletion
Study: NCT04666701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escócia association
Description: Escócia association tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Ketorolac
Description: Placebo Ketorolac tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ketorolac
Description: Placebo Ketorolac tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Scopolamine
Description: Placebo Scopolamine dragee
Study: NCT05763966

Intervention type: OTHER
Intervention: No intervention
Description: Observational study where participants are followed over time

Intervention type: OTHER
Intervention: No intervention
Description: Observational study where participants are followed over time

Intervention type: OTHER
Intervention: No intervention
Description: Observational study where participants are followed over time
Study: NCT05095909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-compression
Description: Programmable intermittent compression with integrated cryo-therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryo-therapy
Description: Subjects are fitted with gel ice packs and wraps.
Study: NCT04666701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Scopolamine
Description: Placebo Scopolamine dragee
Study: NCT05016154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Group CBT intervention
Description: Group of participants complete 10 weeks of Online Group CBT intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SilverCloud guided
Description: Group of participants make use of the SilverCloud guided app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SilverCloud Unguided
Description: Group of participants make use of the SilverCloud Unguided app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Flow
Description: Group of participants make use of the Mood Flow app
Study: NCT06472401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Learning Support System
Description: Students will receive simulation preparation with an Integrated Learning Support System consisting of:~* Educational technology in comic book format~* Virtual monitoring system with tutors~* Psychological follow-up~* Music listening and relaxation session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Learning Model
Description: Students will receive standard simulation preparation consisting of:~- Expository and dialogued theoretical class.
Study: NCT05085119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stepwise modifications of FiO2
Description: FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
Study: NCT04666701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: Ketorolac tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine dragee

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Escócia association
Description: Placebo Escócia association tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Escócia association
Description: Placebo Escócia association tablet
Study: NCT05650645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinum toxin A
Description: The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Saline
Description: Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.